Anika Reports Inducement Grants Under Nasdaq Listing Rule

Biotech company announces new hire stock grants as employment incentive

Apr. 6, 2026 at 3:54am

Got story updates? Submit your updates here. ›

Anika Therapeutics, Inc., a global leader in osteoarthritis pain management and regenerative solutions, announced that on April 1, 2026, the company granted restricted stock units (RSUs) covering an aggregate of 3,138 shares of common stock to one newly hired non-executive employee. The grants were made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.

Why it matters

Anika's announcement of these inducement grants highlights the company's strategy of using equity-based compensation to attract and retain top talent in the competitive biotech industry. As a public company, Anika must comply with Nasdaq listing rules around such grants to new hires.

The details

The RSUs will vest in three equal installments on each of the first three anniversaries of the grant date, as long as the grantee provides continuous service to Anika through the relevant vesting date. The RSUs are subject to the terms and conditions of the equity award agreement approved by Anika and were granted pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, which was not subject to stockholder approval.

  • On April 1, 2026, Anika granted the RSUs.

The players

Anika Therapeutics, Inc.

A global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics.

Got photos? Submit your photos here. ›

The takeaway

Anika's use of inducement grants to attract new talent highlights the competitive nature of the biotech industry and the company's strategy of leveraging equity-based compensation to build its workforce and advance its mission of delivering innovative orthopedic solutions.